Is Amwill Health overvalued or undervalued?

As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics, with a PE ratio of 9.69, an EV to EBIT of 9.02, and an ROCE of 16.92%. Compared to its peers, Amwill Health's valuation stands out; for instance, Sun Pharma is considered expensive with a PE ratio of 35.55, while Dr. Reddy's Labs is very attractive with a PE of 18.88.
In the context of the broader market, Amwill Health's stock has shown a return of 0.97% over the past week, outperforming the Sensex, which returned 0.31%. However, the company's performance over the last month has lagged, with a decline of 11.79% compared to a 3.05% increase in the Sensex. Overall, Amwill Health appears to be fairly valued in the current market landscape.